Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

BACKGROUND: Bevacizumab is the representative drug in antiangiogenic therapy for lung cancer. However, it induced resistance in some neoplasm. Anlotinib, a novel multi-target tyrosine kinase inhibitor which has an inhibitory action on both angiogenesis and malignancy, is possible to reverse the resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhujun, Qin, Tingting, Yuan, Xiaohan, Yang, Jie, Shi, Wei, Zhang, Xiaoling, Jia, Yanan, Liu, Shaochuan, Wang, Jing, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158131/
https://www.ncbi.nlm.nih.gov/pubmed/35664796
http://dx.doi.org/10.3389/fonc.2022.875888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158131/
https://www.ncbi.nlm.nih.gov/pubmed/35664796
http://dx.doi.org/10.3389/fonc.2022.875888

Ejemplares similares